Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 57INDUSTRY 23OTHER_GOV 2NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Multiple Myeloma 1High Grade Squamous Intra-epithelial Lesion (HSIL) 1Disease Progression 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × pomalidomide × Clear all
NCT03113942 2022-03-31

SPACE

Kirby Institute

Phase 2 Unknown
26 enrolled

High Grade Squamous Intra-epithelial Lesion (HSIL)

NCT03601624 2018-11-14

MM-POM-2018

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

Phase 2 Unknown
18 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡